INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 10 hours ago

argenx: 3 Key Takeaways for Long-Term Investors

Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.

The Motley Fool • Oct 23, 2026

Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans

Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.

Investors Business Daily • Oct 22, 2026

What argenex (ARGX) Said on Its Q3 Earnings Call

argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.

MarketBeat • Oct 22, 2026

argenx SE (ARGX) Q3 2026 Earnings Call Transcript

argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Paribas, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Jing Deng Sean Laaman - Morgan Stanley, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Douglas Tsao - H.C.

Seeking Alpha • Oct 22, 2026

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 22, 2026

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.

GlobeNewsWire • Oct 15, 2026

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.

Business Wire • Oct 12, 2026

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.

Zacks Investment Research • Oct 9, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

Zacks Investment Research • Oct 9, 2026